up-to-date with a click!
Update March, 2019
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications March 2019

Add on treatments

  1. Knapik-Kowalczuk J, Chmiel K, Jurkiewicz K et al. Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System. Pharmaceuticals (Basel, Switzerland) 2019; 12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30893881
  2. Martin Navarro JA, Gutierrez Sanchez MJ, Petkov Stoyanov V, Jimenez Herrero MC. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30798999
  3. Ray KK, Bays HE, Catapano AL et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380:1022-1032. http://www.ncbi.nlm.nih.gov/pubmed/?term=30865796
  4. Mani P, Puri R, Schwartz GG et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30840024
  5. Bhatt DL, Steg PG, Miller M et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898607
  6. Ihm SH, Shin J, Park CG, Kim CH. Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito((R))) in Korean adults with hypertension and hypercholesterolemia. Drug design, development and therapy 2019; 13:633-645. http://www.ncbi.nlm.nih.gov/pubmed/?term=30858694
  7. Lorenzatti AJ, Eliaschewitz FG, Chen Y et al. Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821053
  8. Lan NS, Fegan PG, Yeap BB et al. Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834678
  9. Chen Y, Yuan Z, Lu J et al. Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851062

Adherence

  1. Chen ST, Huang ST, Shau WY et al. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan. BMC Cardiovasc Disord 2019; 19:62. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876393
  2. Godinho R, Bugnon S, Gracin T, Tataw J. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya(R) (EVG/COBI/FTC/TAF) and simvastatin; a case report. BMC Nephrol 2019; 20:69. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808332
  3. Torres-Robles A, Wiecek E, Cutler R et al. Using Dispensing Data to Evaluate Adherence Implementation Rates in Community Pharmacy. Frontiers in pharmacology 2019; 10:130. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863308
  4. Hopkin G, Au A, Collier VJ et al. Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. Med Decis Making 2019:272989x19835239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30873906  
 Atherosclerosis & Imaging
  1. Kurihara O, Thondapu V, Kim HO et al. Comparison of Vascular Response to Statin Therapy in Patients With Versus Without Diabetes Mellitus. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851939
  2. Thondapu V, Kurihara O, Yonetsu T et al. Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851941
  3. Lin A, Nerlekar N, Rajagopalan A et al. Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. Atherosclerosis 2019; 284:24-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870704
  4. Tian J, Wang X, Tian J, Yu B. Gender differences in plaque characteristics of nonculprit lesions in patients with coronary artery disease. BMC Cardiovasc Disord 2019; 19:45. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808307
  5. Lo-Kioeng-Shioe MS, Vavere AL, Arbab-Zadeh A et al. Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE 320 Multinational Study. J Am Heart Assoc 2019; 8:e007201. http://www.ncbi.nlm.nih.gov/pubmed/?term=30879377
  6. Dudum R, Whelton SP. Non-statin lipid lowering and coronary plaque composition. Journal of cardiovascular computed tomography 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30803836

Atorvastatin/Rosuvastatin

  1. Zarganes-Tzitzikas T, Neochoritis CG, Domling A. Atorvastatin (Lipitor) by MCR. ACS medicinal chemistry letters 2019; 10:389-392. http://www.ncbi.nlm.nih.gov/pubmed/?term=30891146
  2. Thondapu V, Kurihara O, Yonetsu T et al. Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851941
  3. Hu F, Hu Y, Peng F. Synergistic and protective effect of atorvastatin and amygdalin against histopathological and biochemical alterations in Sprague-Dawley rats with experimental endometriosis. AMB Express 2019; 9:37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888523
  4. Wei W, Peng J, Shen T. Rosuvastatin Alleviates Ischemia/Reperfusion Injury in Cardiomyocytes by Downregulating Hsa-miR-24-3p to Target Upregulated Uncoupling Protein 2. Cellular reprogramming 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30835496
  5. Chen Y, Yuan Z, Lu J et al. Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851062
  6. Ihm SH, Shin J, Park CG, Kim CH. Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito((R))) in Korean adults with hypertension and hypercholesterolemia. Drug design, development and therapy 2019; 13:633-645. http://www.ncbi.nlm.nih.gov/pubmed/?term=30858694
  7. Wu SY, Fang SC, Shih HJ et al. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827745
  8. Yakimenko capital O C, Maznichenko I. Evaluation of Treatment Efficacy in Patients with Non-Alcoholic-Steatohepatitis and Heterozygotic Familial Hypercholesterolemia. Georgian medical news 2019:67-72. http://www.ncbi.nlm.nih.gov/pubmed/?term=30829592
  9. Kwak A, Kim JH, Choi CU et al. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over. Int J Clin Pharm 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30864086
  10. Al-Kuraishy HM, Al-Gareeb AI. Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect. Journal of advanced pharmaceutical technology & research 2019; 10:33-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=30815386
  11. Zhu K, Qian L, Lin Y et al. Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. Journal of diabetes research 2019; 2019:5245063. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863781
  12. Wang J, Cheng X, Zhang X et al. A combination of indomethacin and atorvastatin ameliorates cognitive and pathological deterioration in PrP-hAbetaPPswe/PS1(DeltaE9) transgenic mice. Journal of neuroimmunology 2019; 330:108-115. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870684
  13. Mani P, Puri R, Schwartz GG et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30840024
  14. Kalani MM, Nourmohammadi J, Negahdari B et al. Electrospun core-sheath poly(vinyl alcohol)/silk fibroin nanofibers with Rosuvastatin release functionality for enhancing osteogenesis of human adipose-derived stem cells. Materials science & engineering. C, Materials for biological applications 2019; 99:129-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30889664
  15. Zvizdic F, Godinjak A, Durak-Nalbantic A et al. Impact of Different Types of Statins on Clinical Outcomes in Patients Hospitalized for Ischemic Heart Failure. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:401-405. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814769
  16. Feng PF, Zhang B, Zhao L et al. Intracellular mechanism of rosuvastatin-induced decrease in mature hERG protein expression on membrane. Molecular pharmaceutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30807184
  17. Martin Navarro JA, Gutierrez Sanchez MJ, Petkov Stoyanov V, Jimenez Herrero MC. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30798999
  18. Liu H, Yang J, Wang K et al. Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation. Neurochemical research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30820818
  19. Kluger G, von Stulpnagel-Steinbeis C, Arnold S et al. Positive Short-Term Effect of Low-Dose Rosuvastatin in a Patient with SYNGAP1-Associated Epilepsy. Neuropediatrics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875700
  20. Biselli-Chicote PM, Lotierzo AT, Biselli JM et al. Atorvastatin increases oxidative stress and inhibits cell migration of oral squamous cell carcinoma in vitro. Oral oncology 2019; 90:109-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846168
  21. Cho O, Jang YJ, Park KY, Heo TH. Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. Pharmacological reports : PR 2018; 71:266-271. http://www.ncbi.nlm.nih.gov/pubmed/?term=30822620

Basic science

  1. Zarganes-Tzitzikas T, Neochoritis CG, Domling A. Atorvastatin (Lipitor) by MCR. ACS medicinal chemistry letters 2019; 10:389-392. http://www.ncbi.nlm.nih.gov/pubmed/?term=30891146
  2. Zhu P, Huang G, Zhang B et al. Assessment of fracture healing properties of lovastatin loaded nanoparticles: preclinical study in rat model. Acta biochimica Polonica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30856636
  3. Hu F, Hu Y, Peng F. Synergistic and protective effect of atorvastatin and amygdalin against histopathological and biochemical alterations in Sprague-Dawley rats with experimental endometriosis. AMB Express 2019; 9:37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888523
  4. Liang CL, Chen HJ, Liliang PC et al. Simvastatin and Simvastatin-Ezetimibe Improve the Neurological Function and Attenuate the Endothelial Inflammatory Response after Spinal Cord Injury in Rat. Annals of clinical and laboratory science 2019; 49:105-111. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814085
  5. Hu K, Wan Q. Biphasic influence of pravastatin on human cardiac microvascular endothelial cell functions under pathological and physiological conditions. Biochem Biophys Res Commun 2019; 511:476-481. http://www.ncbi.nlm.nih.gov/pubmed/?term=30803760
  6. Lu L, Huang W, Hu W et al. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer. Biochem Biophys Res Commun 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30833076
  7. Liao Y, Ouyang L, Ci L et al. Pravastatin regulates host foreign-body reaction to polyetheretherketone implants via miR-29ab1-mediated SLIT3 upregulation. Biomaterials 2019; 203:12-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851489
  8. Zhang T, Gillies M, Wang Y et al. Simvastatin Protects Photoreceptors from all-trans-retinal Induced Oxidative Stress with Up-regulation of Interphotoreceptor Retinoid Binding Protein. Br J Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30825184
  9. Wei W, Peng J, Shen T. Rosuvastatin Alleviates Ischemia/Reperfusion Injury in Cardiomyocytes by Downregulating Hsa-miR-24-3p to Target Upregulated Uncoupling Protein 2. Cellular reprogramming 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30835496
  10. Huai J, Yang Z, Yi YH, Wang GJ. Role of mammalian target of rapamycin signaling pathway in regulation of fatty acid oxidation in a preeclampsia-like mouse model treated with pravastatin. Chinese medical journal 2019; 132:671-679. http://www.ncbi.nlm.nih.gov/pubmed/?term=30855348
  11. Beg S, Alam MN, Ahmad FJ, Singh B. Chylomicron mimicking nanocolloidal carriers of rosuvastatin calcium for lymphatic drug targeting and management of hyperlipidemia. Colloids and surfaces. B, Biointerfaces 2019; 177:541-549. http://www.ncbi.nlm.nih.gov/pubmed/?term=30825846
  12. Real J, Miranda C, Olofsson CS, Smith PA. Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion; statins as a test case. Endocrinology, diabetes & metabolism 2018; 1:e00017. http://www.ncbi.nlm.nih.gov/pubmed/?term=30815553
  13. Beltran D, Frutos-Lison MD, Espin JC, Garcia-Villalba R. Re-examining the role of the gut microbiota in the conversion of the lipid-lowering statin monacolin K (lovastatin) into its active beta-hydroxy acid metabolite. Food & function 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30882807
  14. Nezic L, Amidzic L, Skrbic R et al. Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-kappaB/p65 Expression. Frontiers in pharmacology 2019; 10:54. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828299
  15. Sroda-Pomianek K, Michalak K, Palko-Labuz A et al. The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30813251
  16. de Miranda JR, Choi IGG, Moreira MS et al. Histologic Evaluation of Early Bone Regeneration Treated with Simvastatin Associated with Low-Level Laser Therapy. The International journal of oral & maxillofacial implants 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30892287
  17. Al-Kuraishy HM, Al-Gareeb AI. Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect. Journal of advanced pharmaceutical technology & research 2019; 10:33-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=30815386
  18. Tsubaki M, Takeda T, Obata N et al. Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma. Journal of cellular physiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834527
  19. Cook EH, Masaki JT, Guter SJ, Najjar F. Lovastatin Treatment of a Patient with a De Novo SYNGAP1 Protein Truncating Variant. Journal of child and adolescent psychopharmacology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30901256
  20. Zhu K, Qian L, Lin Y et al. Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. Journal of diabetes research 2019; 2019:5245063. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863781
  21. Parks XX, Ronzier E, J OU, Lopes CM. Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca(2+)-dependent PKC activation. Journal of molecular and cellular cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898664
  22. Wang J, Cheng X, Zhang X et al. A combination of indomethacin and atorvastatin ameliorates cognitive and pathological deterioration in PrP-hAbetaPPswe/PS1(DeltaE9) transgenic mice. Journal of neuroimmunology 2019; 330:108-115. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870684
  23. Tradtrantip L, Duan T, Yeaman MR, Verkman AS. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. Journal of neuroinflammation 2019; 16:57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851734
  24. Kalani MM, Nourmohammadi J, Negahdari B et al. Electrospun core-sheath poly(vinyl alcohol)/silk fibroin nanofibers with Rosuvastatin release functionality for enhancing osteogenesis of human adipose-derived stem cells. Materials science & engineering. C, Materials for biological applications 2019; 99:129-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30889664
  25. Mallappa S, Neeli PK, Karnewar S, Kotamraju S. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization. Molecular carcinogenesis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834613
  26. Feng PF, Zhang B, Zhao L et al. Intracellular mechanism of rosuvastatin-induced decrease in mature hERG protein expression on membrane. Molecular pharmaceutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30807184
  27. Liu H, Yang J, Wang K et al. Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation. Neurochemical research 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30820818
  28. Kanda T, Sugihara T, Takata T et al. Low-density lipoprotein receptor expression is involved in the beneficial effect of photodynamic therapy using talaporfin sodium on gastric cancer cells. Oncology letters 2019; 17:3261-3266. http://www.ncbi.nlm.nih.gov/pubmed/?term=30867758
  29. Xiao A, Brenneman B, Floyd D et al. Statins affect human glioblastoma and other cancers through TGF-beta inhibition. Oncotarget 2019; 10:1716-1728. http://www.ncbi.nlm.nih.gov/pubmed/?term=30899443
  30. Biselli-Chicote PM, Lotierzo AT, Biselli JM et al. Atorvastatin increases oxidative stress and inhibits cell migration of oral squamous cell carcinoma in vitro. Oral oncology 2019; 90:109-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846168
  31. Hassan A, Saleem Y, Chaudhry MN et al. Optimization of process variables for increased production of lovastatin in Aspergillus terreus PU-PCSIR1 and its characterization. Pak J Pharm Sci 2019; 32:363-370. http://www.ncbi.nlm.nih.gov/pubmed/?term=30829216
  32. Knapik-Kowalczuk J, Chmiel K, Jurkiewicz K et al. Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System. Pharmaceuticals (Basel, Switzerland) 2019; 12. http://www.ncbi.nlm.nih.gov/pubmed/?term=30893881
  33. Araya-Sibaja AM, Vega-Baudrit JR, Guillen-Giron T et al. Drug Solubility Enhancement through the Preparation of Multicomponent Organic Materials: Eutectics of Lovastatin with Carboxylic Acids. Pharmaceutics 2019; 11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30857331
  34. Naserzadeh R, Abad N, Ghorbanzadeh B et al. Simvastatin exerts antidepressant-like activity in mouse forced swimming test: Role of NO-cGMP-KATP channels pathway and PPAR-gamma receptors. Pharmacology, biochemistry, and behavior 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30857920
  35. Cho O, Jang YJ, Park KY, Heo TH. Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. Pharmacological reports : PR 2018; 71:266-271. http://www.ncbi.nlm.nih.gov/pubmed/?term=30822620
  36. Chang CC, Huang KH, Hsu SP et al. Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Scientific reports 2019; 9:4606. http://www.ncbi.nlm.nih.gov/pubmed/?term=30872677
  37. Iyer S, Donnelly PE, Spaniel G et al. Locally Applied Simvastatin as an Adjunct to Promote Spinal Fusion in Rats. Spine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30896582
  38. Watanabe K, Oda S, Matsubara A et al. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. Toxicology letters 2019; 307:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=30853469
  39. Curry L, Almukhtar H, Alahmed J et al. Simvastatin inhibits L-type Ca2+-channel activity through impairment of mitochondrial function. Toxicological sciences : an official journal of the Society of Toxicology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859212

Cancer

  1. Kim J, You NY, Lee JW et al. Inverse Association Between Statin Use and Overall Cancer Incidence in Individuals With Hypercholesterolemia, Based on the Korean Health Insurance Service Between 2002 and 2015. Asia-Pacific journal of public health 2019:1010539519830235. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808200
  2. Lu L, Huang W, Hu W et al. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer. Biochem Biophys Res Commun 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30833076
  3. Hosio M, Urpilainen E, Marttila M et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Res Treat 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30895533
  4. Lacroix O, Couttenier A, Vaes E et al. Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes Control 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30820714
  5. Ho W, Choo DW, Wu YJ et al. Statins Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan. Clinical pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30801679
  6. Van Rompay MI, Solomon KR, Nickel JC et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30850323
  7. Wu SY, Fang SC, Shih HJ et al. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827745
  8. Jang HS, Choi J, Shin J et al. The Long-Term Effect of Cancer on Incident Stroke: A Nationwide Population-Based Cohort Study in Korea. Frontiers in neurology 2019; 10:52. http://www.ncbi.nlm.nih.gov/pubmed/?term=30804874
  9. Cheung KS, Chen L, Chan EW et al. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808646
  10. Jang HJ. Can Statin Prevent the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Disease? Gut Liver 2019; 13:138-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30893984
  11. Kao LT, Hung SH, Kao PF et al. Inverse association between statin use and head and neck cancer: A population-based case-control study in Han population. Head & neck 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30809863
  12. Kirkegard J, Lund JL, Mortensen FV, Cronin-Fenton D. Statins and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis: A Danish nationwide population-based cohort study. International journal of cancer. Journal international du cancer 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30861115
  13. Tsubaki M, Takeda T, Obata N et al. Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma. Journal of cellular physiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834527
  14. Mallappa S, Neeli PK, Karnewar S, Kotamraju S. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization. Molecular carcinogenesis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834613
  15. Henker C, Kriesen T, Scherer M et al. Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. Neurosurgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888031
  16. Kanda T, Sugihara T, Takata T et al. Low-density lipoprotein receptor expression is involved in the beneficial effect of photodynamic therapy using talaporfin sodium on gastric cancer cells. Oncology letters 2019; 17:3261-3266. http://www.ncbi.nlm.nih.gov/pubmed/?term=30867758
  17. Xiao A, Brenneman B, Floyd D et al. Statins affect human glioblastoma and other cancers through TGF-beta inhibition. Oncotarget 2019; 10:1716-1728. http://www.ncbi.nlm.nih.gov/pubmed/?term=30899443
  18. Biselli-Chicote PM, Lotierzo AT, Biselli JM et al. Atorvastatin increases oxidative stress and inhibits cell migration of oral squamous cell carcinoma in vitro. Oral oncology 2019; 90:109-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846168
  19. Gupta A, Stokes W, Eguchi M et al. Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral oncology 2019; 90:54-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846177

Children

  1. Coakley JC. Lipids in Children and Links to Adult Vascular Disease. The Clinical biochemist. Reviews 2018; 39:65-76. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828113
  2. Miedema MD, Nauffal VD, Singh A, Blankstein R. Statin therapy for young adults: A long-term investment worth considering. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808553
  3. Yeboah J. Statin for primary prevention of atherosclerotic cardiovascular disease in young adults: Are we there yet? Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876793

Cost-effectiveness

  1. Jiang Y, Ni W. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. PharmacoEconomics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875022

CVD

  1. Coakley JC. Lipids in Children and Links to Adult Vascular Disease. The Clinical biochemist. Reviews 2018; 39:65-76. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828113
  2. Kwak A, Kim JH, Choi CU et al. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over. Int J Clin Pharm 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30864086
  3. Jukema JW, Szarek M, Zijlstra LE et al. Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898609
  4. Amioka N, Miyoshi T, Otsuka H et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898480
  5. Jeong HS, Hong SJ. Benefit of Early Statin Therapy in Acute Myocardial Infarction in Korea. Korean Circ J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30891965
  6. Kim MC, Ahn Y, Cho JY et al. Benefit of Early Statin Initiation within 48 Hours after Admission in Statin-Naive Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Korean Circ J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808084
  7. Zvizdic F, Godinjak A, Durak-Nalbantic A et al. Impact of Different Types of Statins on Clinical Outcomes in Patients Hospitalized for Ischemic Heart Failure. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:401-405. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814769

Endothelium/inflammation

  1. Hu K, Wan Q. Biphasic influence of pravastatin on human cardiac microvascular endothelial cell functions under pathological and physiological conditions. Biochem Biophys Res Commun 2019; 511:476-481. http://www.ncbi.nlm.nih.gov/pubmed/?term=30803760
  2. Arnold N, Koenig W. [Atherosclerosis as an Inflammatory Disease - Pathophysiology, Clinical Relevance and Therapeutic Implications]. Deutsche medizinische Wochenschrift (1946) 2019; 144:315-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=30836402
  3. Kim SW, Kang HJ, Jhon M et al. Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Frontiers in psychiatry 2019; 10:103. http://www.ncbi.nlm.nih.gov/pubmed/?term=30890971
  4. Mani P, Puri R, Schwartz GG et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30840024
  5. Cho O, Jang YJ, Park KY, Heo TH. Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. Pharmacological reports : PR 2018; 71:266-271. http://www.ncbi.nlm.nih.gov/pubmed/?term=30822620

Ethnicity

  1. Kim J, You NY, Lee JW et al. Inverse Association Between Statin Use and Overall Cancer Incidence in Individuals With Hypercholesterolemia, Based on the Korean Health Insurance Service Between 2002 and 2015. Asia-Pacific journal of public health 2019:1010539519830235. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808200
  2. Hamoui O, Omar MI, Raal FJ et al. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord 2019; 19:61. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876390
  3. Son KB, Bae S. Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. BMJ Open 2019; 9:e026603. http://www.ncbi.nlm.nih.gov/pubmed/?term=30842117
  4. Ho W, Choo DW, Wu YJ et al. Statins Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan. Clinical pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30801679
  5. Chen Y, Yuan Z, Lu J et al. Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851062
  6. Kawasaki R, Kitano S, Sato Y et al. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetology international 2019; 10:3-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30800559
  7. Jiang Y, Ni W. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. PharmacoEconomics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875022
  8. Lundberg E, Hagberg O, Jahnson S, Ljungberg B. Association between occurrence of urinary bladder cancer and treatment with statin medication. Turkish journal of urology 2019; 45:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875287

Guidelines

  1. Hamoui O, Omar MI, Raal FJ et al. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord 2019; 19:61. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876390
  2. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 2019:Cir0000000000000678. http://www.ncbi.nlm.nih.gov/pubmed/?term=30879355
  3. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Circulation 2019:Cir0000000000000677. http://www.ncbi.nlm.nih.gov/pubmed/?term=30879339
  4. Khan NNS, Kelly-Blake K, Luo Z, Olomu A. Sex Differences in Statin Prescribing in Diabetic and Heart Disease Patients in FQHCs: A Comparison of the ATPIII and 2013 ACC/AHA Cholesterol Guidelines. Health services research and managerial epidemiology 2019; 6:2333392818825414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859113
  5. Lopez-Jaramillo P, Barbosa E, Molina DI et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. J Hypertens 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30882601

LDL- related parameters

  1. Suzuki K, Oikawa T, Nochioka K et al. Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. Arterioscler Thromb Vasc Biol 2019:Atvbaha119312336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30866657
  2. Lin A, Nerlekar N, Rajagopalan A et al. Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. Atherosclerosis 2019; 284:24-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870704
  3. Csaszar A. The characteristics of two LDL-cholesterol level reduction treatment strategies, "treat-to-target" and "percent reduction": an observational study without intervention. BMC Cardiovasc Disord 2019; 19:57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30857520
  4. Reiner Z. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk? Curr Atheroscler Rep 2019; 21:14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30847681
  5. Khan NNS, Kelly-Blake K, Luo Z, Olomu A. Sex Differences in Statin Prescribing in Diabetic and Heart Disease Patients in FQHCs: A Comparison of the ATPIII and 2013 ACC/AHA Cholesterol Guidelines. Health services research and managerial epidemiology 2019; 6:2333392818825414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859113
  6. Chan DC, Watts GF, Coll B et al. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. J Am Heart Assoc 2019; 8:e011781. http://www.ncbi.nlm.nih.gov/pubmed/?term=30897995
  7. Khan SU, Rahman H, Okunrintemi V et al. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2019; 8:e011581. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898075
  8. Yamamoto H, Kawamura M, Kochi I et al. Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30867375
  9. Amioka N, Miyoshi T, Otsuka H et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898480
  10. Tomoi Y, Yamaji K, Soga Y et al. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 2019:1526602819836382. http://www.ncbi.nlm.nih.gov/pubmed/?term=30873910
  11. Judge C, Ruttledge S, Costello M et al. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30878368

Meta-analyses

  1. Riaz H, Khan SU, Rahman H et al. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol 2018:2047487318816495. http://www.ncbi.nlm.nih.gov/pubmed/?term=30861690
  2. Khan SU, Rahman H, Okunrintemi V et al. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2019; 8:e011581. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898075
  3. Judge C, Ruttledge S, Costello M et al. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30878368
  4. Yan J, Qiao L, Tian J et al. Effect of statins on Parkinson's disease: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98:e14852. http://www.ncbi.nlm.nih.gov/pubmed/?term=30896628
  5. Fogacci F, Banach M, Mikhailidis DP et al. Safety of Red Yeast Rice Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacol Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30844537
  6. Kockerling D, Nathwani R, Forlano R et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25:888-908. http://www.ncbi.nlm.nih.gov/pubmed/?term=30833797

Metabolic Syndrome - Diabetes

  1. Kurihara O, Thondapu V, Kim HO et al. Comparison of Vascular Response to Statin Therapy in Patients With Versus Without Diabetes Mellitus. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851939
  2. Alexopoulos AS, Qamar A, Hutchins K et al. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Current diabetes reports 2019; 19:13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30806837
  3. Femlak M, Gluba-Brzozka A, Franczyk B, Rysz J. Diabetes-induced Alterations in HDL Subfractions Distribution. Current pharmaceutical design 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827232
  4. Lan NS, Fegan PG, Yeap BB et al. Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834678
  5. Lorenzatti AJ, Eliaschewitz FG, Chen Y et al. Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821053
  6. Kawasaki R, Kitano S, Sato Y et al. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetology international 2019; 10:3-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30800559
  7. Real J, Miranda C, Olofsson CS, Smith PA. Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion; statins as a test case. Endocrinology, diabetes & metabolism 2018; 1:e00017. http://www.ncbi.nlm.nih.gov/pubmed/?term=30815553
  8. Khalil S, Khayyat S, Al-Khadra Y, Alraies MC. Should all diabetic patients take statin therapy regardless of serum cholesterol level? Expert Rev Cardiovasc Ther 2019:1-3. http://www.ncbi.nlm.nih.gov/pubmed/?term=30856356
  9. Abed E, LaBarbera B, Dvorak J et al. Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J Pediatr Endocrinol Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30860978

New Treatments

  1. Ferrari F, Stein R, Motta MT, Moriguchi EH. PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice. Arquivos brasileiros de cardiologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30843929
  2. Gencer B, Pagano S, Vuilleumier N et al. Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naive of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827714
  3. Dixon DL, Pamulapati LG, Bucheit JD et al. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. Curr Atheroscler Rep 2019; 21:16. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877491
  4. Reiner Z. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk? Curr Atheroscler Rep 2019; 21:14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30847681
  5. Nicholls SJ. The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. Current cardiology reports 2019; 21:18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828741
  6. Alexopoulos AS, Qamar A, Hutchins K et al. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Current diabetes reports 2019; 19:13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30806837
  7. Chen Y, Yuan Z, Lu J et al. Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851062
  8. Lorenzatti AJ, Eliaschewitz FG, Chen Y et al. Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821053
  9. Ruscica M, Banach M, Sahebkar A et al. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother 2019:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30810432
  10. Wong ND, Shapiro MD. Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. Frontiers in cardiovascular medicine 2019; 6:14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30895178
  11. Jukema JW, Szarek M, Zijlstra LE et al. Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898609
  12. Dudum R, Whelton SP. Non-statin lipid lowering and coronary plaque composition. Journal of cardiovascular computed tomography 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30803836
  13. Zhu K, Qian L, Lin Y et al. Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. Journal of diabetes research 2019; 2019:5245063. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863781
  14. Ray KK, Bays HE, Catapano AL et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380:1022-1032. http://www.ncbi.nlm.nih.gov/pubmed/?term=30865796
  15. Sabouret P, Farnier M, Puymirat E. [PCSK9 inhibitors: What place in the management of dyslipidemia?]. Presse medicale (Paris, France : 1983) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30853281

Other

  1. Son KB, Bae S. Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. BMJ Open 2019; 9:e026603. http://www.ncbi.nlm.nih.gov/pubmed/?term=30842117
  2. Kim KM, Jung KY, Yun HM et al. Retraction Note: Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report. Cardiovascular diabetology 2019; 18:32. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876421
  3. Yamamoto H, Kawamura M, Kochi I et al. Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30867375
  4. Hopkin G, Au A, Collier VJ et al. Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. Med Decis Making 2019:272989x19835239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30873906
  5. Adam TJ, Chi CL. Big Data Cohort Extraction for Personalized Statin Treatment and Machine Learning. Methods in molecular biology (Clifton, N.J.) 2019; 1939:255-272. http://www.ncbi.nlm.nih.gov/pubmed/?term=30848466
  6. Nam YH, Bilker WB, Leonard CE et al. Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study. Scientific reports 2019; 9:4685. http://www.ncbi.nlm.nih.gov/pubmed/?term=30886182
  7. Suppressa P, Carbonara C, Lugani F et al. Congenital analbuminemia in a patient affected by hypercholesterolemia: A case report. World journal of clinical cases 2019; 7:466-472. http://www.ncbi.nlm.nih.gov/pubmed/?term=30842957

PAD and statins

  1. Tomoi Y, Yamaji K, Soga Y et al. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 2019:1526602819836382. http://www.ncbi.nlm.nih.gov/pubmed/?term=30873910
  2. Parks XX, Ronzier E, J OU, Lopes CM. Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca(2+)-dependent PKC activation. Journal of molecular and cellular cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898664
  3. Abdelkarim AH, Dakour-Aridi H, Gurakar M et al. Association between statin use and perioperative mortality after aortobifemoral bypass in patients with aortoiliac occlusive disease. Journal of vascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30837182

Pleiotropic effects of statins

  1. Zhu P, Huang G, Zhang B et al. Assessment of fracture healing properties of lovastatin loaded nanoparticles: preclinical study in rat model. Acta biochimica Polonica 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30856636
  2. Huang CH, Yu PH, Tsai MS et al. Relationship Between Statin Use and Outcomes in Patients Having Cardiac Arrest (from a Nationwide Cohort Study in Taiwan). Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851940
  3. Hu F, Hu Y, Peng F. Synergistic and protective effect of atorvastatin and amygdalin against histopathological and biochemical alterations in Sprague-Dawley rats with experimental endometriosis. AMB Express 2019; 9:37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888523
  4. Liang CL, Chen HJ, Liliang PC et al. Simvastatin and Simvastatin-Ezetimibe Improve the Neurological Function and Attenuate the Endothelial Inflammatory Response after Spinal Cord Injury in Rat. Annals of clinical and laboratory science 2019; 49:105-111. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814085
  5. Kim J, You NY, Lee JW et al. Inverse Association Between Statin Use and Overall Cancer Incidence in Individuals With Hypercholesterolemia, Based on the Korean Health Insurance Service Between 2002 and 2015. Asia-Pacific journal of public health 2019:1010539519830235. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808200
  6. Chung CM, Lin MS, Lin YS. Reply to: "An update on statins: Pleiotropic effect on intracerebral hemorrhage". Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898359
  7. Lu L, Huang W, Hu W et al. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer. Biochem Biophys Res Commun 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30833076
  8. Zhang T, Gillies M, Wang Y et al. Simvastatin Protects Photoreceptors from all-trans-retinal Induced Oxidative Stress with Up-regulation of Interphotoreceptor Retinoid Binding Protein. Br J Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30825184
  9. Lacroix O, Couttenier A, Vaes E et al. Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes Control 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30820714
  10. Wei W, Peng J, Shen T. Rosuvastatin Alleviates Ischemia/Reperfusion Injury in Cardiomyocytes by Downregulating Hsa-miR-24-3p to Target Upregulated Uncoupling Protein 2. Cellular reprogramming 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30835496
  11. Huai J, Yang Z, Yi YH, Wang GJ. Role of mammalian target of rapamycin signaling pathway in regulation of fatty acid oxidation in a preeclampsia-like mouse model treated with pravastatin. Chinese medical journal 2019; 132:671-679. http://www.ncbi.nlm.nih.gov/pubmed/?term=30855348
  12. Kawasaki R, Kitano S, Sato Y et al. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetology international 2019; 10:3-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30800559
  13. Van Rompay MI, Solomon KR, Nickel JC et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30850323
  14. Wu SY, Fang SC, Shih HJ et al. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827745
  15. Nezic L, Amidzic L, Skrbic R et al. Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-kappaB/p65 Expression. Frontiers in pharmacology 2019; 10:54. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828299
  16. Kim SW, Kang HJ, Jhon M et al. Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Frontiers in psychiatry 2019; 10:103. http://www.ncbi.nlm.nih.gov/pubmed/?term=30890971
  17. Yakimenko capital O C, Maznichenko I. Evaluation of Treatment Efficacy in Patients with Non-Alcoholic-Steatohepatitis and Heterozygotic Familial Hypercholesterolemia. Georgian medical news 2019:67-72. http://www.ncbi.nlm.nih.gov/pubmed/?term=30829592
  18. Cheung KS, Chen L, Chan EW et al. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808646
  19. Jang HJ. Can Statin Prevent the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Disease? Gut Liver 2019; 13:138-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30893984
  20. Kao LT, Hung SH, Kao PF et al. Inverse association between statin use and head and neck cancer: A population-based case-control study in Han population. Head & neck 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30809863
  21. Durand M, Machuron C, Guillet L et al. Preoperative Statin Treatment Is Not Associated with Reduced Postoperative Mortality or Morbidity in Patients Undergoing Isolated Valve Surgery. The heart surgery forum 2019; 22:E057-e062. http://www.ncbi.nlm.nih.gov/pubmed/?term=30802199
  22. Kwon OC, Oh JS, Park MC et al. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30824260
  23. de Miranda JR, Choi IGG, Moreira MS et al. Histologic Evaluation of Early Bone Regeneration Treated with Simvastatin Associated with Low-Level Laser Therapy. The International journal of oral & maxillofacial implants 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30892287
  24. Al-Kuraishy HM, Al-Gareeb AI. Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect. Journal of advanced pharmaceutical technology & research 2019; 10:33-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=30815386
  25. Tsubaki M, Takeda T, Obata N et al. Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma. Journal of cellular physiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834527
  26. Al-Khazaali A, Situala S, Dhindsa S. Letter to the Editor: [Association Between Cortical Bone Microstructure and Statin Use in Older Women]. J Clin Endocrinol Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30848797
  27. Larsson BAM, Sundh D, Mellstrom D et al. Response to Letter: Association between cortical bone microstructure and statin use in older women. J Clin Endocrinol Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30848828
  28. Tradtrantip L, Duan T, Yeaman MR, Verkman AS. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. Journal of neuroinflammation 2019; 16:57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851734
  29. Cook MJ, Sorial AK, Lunt M et al. Effect of timing and duration of statin exposure on risk of hip or knee revision arthroplasty: a population-based cohort study. The Journal of rheumatology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877207
  30. Offer A, Arnold M, Clarke R et al. Assessement of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA network open 2019; 2:e190223. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821829
  31. Kalani MM, Nourmohammadi J, Negahdari B et al. Electrospun core-sheath poly(vinyl alcohol)/silk fibroin nanofibers with Rosuvastatin release functionality for enhancing osteogenesis of human adipose-derived stem cells. Materials science & engineering. C, Materials for biological applications 2019; 99:129-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30889664
  32. Feng PF, Zhang B, Zhao L et al. Intracellular mechanism of rosuvastatin-induced decrease in mature hERG protein expression on membrane. Molecular pharmaceutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30807184
  33. Bosch J, O'Donnell M, Swaminathan B et al. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814321
  34. Kluger G, von Stulpnagel-Steinbeis C, Arnold S et al. Positive Short-Term Effect of Low-Dose Rosuvastatin in a Patient with SYNGAP1-Associated Epilepsy. Neuropediatrics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875700
  35. Henker C, Kriesen T, Scherer M et al. Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. Neurosurgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888031
  36. Kanda T, Sugihara T, Takata T et al. Low-density lipoprotein receptor expression is involved in the beneficial effect of photodynamic therapy using talaporfin sodium on gastric cancer cells. Oncology letters 2019; 17:3261-3266. http://www.ncbi.nlm.nih.gov/pubmed/?term=30867758
  37. Xiao A, Brenneman B, Floyd D et al. Statins affect human glioblastoma and other cancers through TGF-beta inhibition. Oncotarget 2019; 10:1716-1728. http://www.ncbi.nlm.nih.gov/pubmed/?term=30899443
  38. Biselli-Chicote PM, Lotierzo AT, Biselli JM et al. Atorvastatin increases oxidative stress and inhibits cell migration of oral squamous cell carcinoma in vitro. Oral oncology 2019; 90:109-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846168
  39. Gupta A, Stokes W, Eguchi M et al. Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral oncology 2019; 90:54-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846177
  40. Naserzadeh R, Abad N, Ghorbanzadeh B et al. Simvastatin exerts antidepressant-like activity in mouse forced swimming test: Role of NO-cGMP-KATP channels pathway and PPAR-gamma receptors. Pharmacology, biochemistry, and behavior 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30857920
  41. Chang CC, Huang KH, Hsu SP et al. Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation. Scientific reports 2019; 9:4606. http://www.ncbi.nlm.nih.gov/pubmed/?term=30872677
  42. Nam YH, Bilker WB, Leonard CE et al. Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study. Scientific reports 2019; 9:4685. http://www.ncbi.nlm.nih.gov/pubmed/?term=30886182
  43. Iyer S, Donnelly PE, Spaniel G et al. Locally Applied Simvastatin as an Adjunct to Promote Spinal Fusion in Rats. Spine 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30896582
  44. Suppressa P, Carbonara C, Lugani F et al. Congenital analbuminemia in a patient affected by hypercholesterolemia: A case report. World journal of clinical cases 2019; 7:466-472. http://www.ncbi.nlm.nih.gov/pubmed/?term=30842957
  45. Kockerling D, Nathwani R, Forlano R et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25:888-908. http://www.ncbi.nlm.nih.gov/pubmed/?term=30833797

Primary Prevention

  1. Kim K, Lee CJ, Shim CY et al. Statin and clinical outcomes of primary prevention in individuals aged >75years: The SCOPE-75 study. Atherosclerosis 2019; 284:31-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870705
  2. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 2019:Cir0000000000000678. http://www.ncbi.nlm.nih.gov/pubmed/?term=30879355
  3. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Circulation 2019:Cir0000000000000677. http://www.ncbi.nlm.nih.gov/pubmed/?term=30879339

Registry data

  1. Kotlega D, Golab-Janowska M, Meller A et al. Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. Archives of medical science : AMS 2019; 15:385-392. http://www.ncbi.nlm.nih.gov/pubmed/?term=30899291
  2. Kim J, You NY, Lee JW et al. Inverse Association Between Statin Use and Overall Cancer Incidence in Individuals With Hypercholesterolemia, Based on the Korean Health Insurance Service Between 2002 and 2015. Asia-Pacific journal of public health 2019:1010539519830235. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808200
  3. Gencer B, Pagano S, Vuilleumier N et al. Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naive of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827714
  4. Chen ST, Huang ST, Shau WY et al. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan. BMC Cardiovasc Disord 2019; 19:62. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876393
  5. Ahmadizar F, OchoaRosales C, Glisic M et al. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30838685
  6. Lacroix O, Couttenier A, Vaes E et al. Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes Control 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30820714
  7. Coakley JC. Lipids in Children and Links to Adult Vascular Disease. The Clinical biochemist. Reviews 2018; 39:65-76. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828113
  8. Ho W, Choo DW, Wu YJ et al. Statins Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan. Clinical pharmacology and therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30801679
  9. Van Rompay MI, Solomon KR, Nickel JC et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30850323
  10. Wu SY, Fang SC, Shih HJ et al. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. European journal of cancer (Oxford, England : 1990) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827745
  11. Sundvall H, Fastbom J, Wallerstedt SM, Vitols S. Use of statins in the elderly according to age and indication-a cross-sectional population-based register study. Eur J Clin Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30826850
  12. Jang HS, Choi J, Shin J et al. The Long-Term Effect of Cancer on Incident Stroke: A Nationwide Population-Based Cohort Study in Korea. Frontiers in neurology 2019; 10:52. http://www.ncbi.nlm.nih.gov/pubmed/?term=30804874
  13. Torres-Robles A, Wiecek E, Cutler R et al. Using Dispensing Data to Evaluate Adherence Implementation Rates in Community Pharmacy. Frontiers in pharmacology 2019; 10:130. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863308
  14. Cheung KS, Chen L, Chan EW et al. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808646
  15. Kao LT, Hung SH, Kao PF et al. Inverse association between statin use and head and neck cancer: A population-based case-control study in Han population. Head & neck 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30809863
  16. Khan NNS, Kelly-Blake K, Luo Z, Olomu A. Sex Differences in Statin Prescribing in Diabetic and Heart Disease Patients in FQHCs: A Comparison of the ATPIII and 2013 ACC/AHA Cholesterol Guidelines. Health services research and managerial epidemiology 2019; 6:2333392818825414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859113
  17. Durand M, Machuron C, Guillet L et al. Preoperative Statin Treatment Is Not Associated with Reduced Postoperative Mortality or Morbidity in Patients Undergoing Isolated Valve Surgery. The heart surgery forum 2019; 22:E057-e062. http://www.ncbi.nlm.nih.gov/pubmed/?term=30802199
  18. Kirkegard J, Lund JL, Mortensen FV, Cronin-Fenton D. Statins and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis: A Danish nationwide population-based cohort study. International journal of cancer. Journal international du cancer 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30861115
  19. Kwon OC, Oh JS, Park MC et al. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30824260
  20. Soohoo M, Moradi H, Obi Y et al. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc 2019; 8:e011869. http://www.ncbi.nlm.nih.gov/pubmed/?term=30885048
  21. Abed E, LaBarbera B, Dvorak J et al. Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J Pediatr Endocrinol Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30860978
  22. Cook MJ, Sorial AK, Lunt M et al. Effect of timing and duration of statin exposure on risk of hip or knee revision arthroplasty: a population-based cohort study. The Journal of rheumatology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877207
  23. Abdelkarim AH, Dakour-Aridi H, Gurakar M et al. Association between statin use and perioperative mortality after aortobifemoral bypass in patients with aortoiliac occlusive disease. Journal of vascular surgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30837182
  24. Offer A, Arnold M, Clarke R et al. Assessement of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA network open 2019; 2:e190223. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821829
  25. Zvizdic F, Godinjak A, Durak-Nalbantic A et al. Impact of Different Types of Statins on Clinical Outcomes in Patients Hospitalized for Ischemic Heart Failure. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:401-405. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814769
  26. Henker C, Kriesen T, Scherer M et al. Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. Neurosurgery 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888031
  27. Gupta A, Stokes W, Eguchi M et al. Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral oncology 2019; 90:54-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=30846177
  28. Jiang Y, Ni W. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. PharmacoEconomics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875022
  29. Nam YH, Bilker WB, Leonard CE et al. Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study. Scientific reports 2019; 9:4685. http://www.ncbi.nlm.nih.gov/pubmed/?term=30886182
  30. Lundberg E, Hagberg O, Jahnson S, Ljungberg B. Association between occurrence of urinary bladder cancer and treatment with statin medication. Turkish journal of urology 2019; 45:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875287

Renal Disease

  1. Soohoo M, Moradi H, Obi Y et al. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc 2019; 8:e011869. http://www.ncbi.nlm.nih.gov/pubmed/?term=30885048
  2. Suppressa P, Carbonara C, Lugani F et al. Congenital analbuminemia in a patient affected by hypercholesterolemia: A case report. World journal of clinical cases 2019; 7:466-472. http://www.ncbi.nlm.nih.gov/pubmed/?term=30842957

Reviews

  1. Ferrari F, Stein R, Motta MT, Moriguchi EH. PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice. Arquivos brasileiros de cardiologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30843929
  2. Dixon DL, Pamulapati LG, Bucheit JD et al. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. Curr Atheroscler Rep 2019; 21:16. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877491
  3. Reiner Z. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk? Curr Atheroscler Rep 2019; 21:14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30847681
  4. Nicholls SJ. The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. Current cardiology reports 2019; 21:18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30828741
  5. Lan NS, Fegan PG, Yeap BB et al. Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30834678
  6. Arnold N, Koenig W. [Atherosclerosis as an Inflammatory Disease - Pathophysiology, Clinical Relevance and Therapeutic Implications]. Deutsche medizinische Wochenschrift (1946) 2019; 144:315-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=30836402
  7. Ruscica M, Banach M, Sahebkar A et al. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother 2019:1-13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30810432
  8. Khalil S, Khayyat S, Al-Khadra Y, Alraies MC. Should all diabetic patients take statin therapy regardless of serum cholesterol level? Expert Rev Cardiovasc Ther 2019:1-3. http://www.ncbi.nlm.nih.gov/pubmed/?term=30856356
  9. Wong ND, Shapiro MD. Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. Frontiers in cardiovascular medicine 2019; 6:14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30895178
  10. Jang HJ. Can Statin Prevent the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Disease? Gut Liver 2019; 13:138-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=30893984
  11. Lopez-Jaramillo P, Barbosa E, Molina DI et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. J Hypertens 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30882601
  12. Seftel AD. Re: Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association. The Journal of urology 2019:10109701ju00005547914083509. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888895
  13. Jeong HS, Hong SJ. Benefit of Early Statin Therapy in Acute Myocardial Infarction in Korea. Korean Circ J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30891965
  14. Comparison table: Some lipid-lowering drugs. The Medical letter on drugs and therapeutics 2019; 61:e24-e30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30845107
  15. Lipid-lowering drugs. The Medical letter on drugs and therapeutics 2019; 61:17-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=30845106
  16. Bouitbir J, Sanvee GM, Panajatovic MV et al. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877064
  17. Lutjohann D, Stellaard F, Mulder MT et al. The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm. Pharmacology & therapeutics 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877023
  18. Sabouret P, Farnier M, Puymirat E. [PCSK9 inhibitors: What place in the management of dyslipidemia?]. Presse medicale (Paris, France : 1983) 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30853281
  19. Ledru F. [Secondary cardiovascular prevention strategies]. Rev Prat 2018; 68:439-445. http://www.ncbi.nlm.nih.gov/pubmed/?term=30869397
  20. Shrestha A, Mulmi A, Munankarmi R. Statins and Abnormal Liver Enzymes. South Dakota medicine : the journal of the South Dakota State Medical Association 2019; 72:12-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30849222
  21. Miedema MD, Nauffal VD, Singh A, Blankstein R. Statin therapy for young adults: A long-term investment worth considering. Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808553
  22. Yeboah J. Statin for primary prevention of atherosclerotic cardiovascular disease in young adults: Are we there yet? Trends Cardiovasc Med 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30876793

Safety and side effects

  1. Godinho R, Bugnon S, Gracin T, Tataw J. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya(R) (EVG/COBI/FTC/TAF) and simvastatin; a case report. BMC Nephrol 2019; 20:69. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808332
  2. Ahmadizar F, OchoaRosales C, Glisic M et al. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30838685
  3. Hosio M, Urpilainen E, Marttila M et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Res Treat 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30895533
  4. Sroda-Pomianek K, Michalak K, Palko-Labuz A et al. The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30813251
  5. Khan SU, Rahman H, Okunrintemi V et al. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2019; 8:e011581. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898075
  6. Zhu K, Qian L, Lin Y et al. Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. Journal of diabetes research 2019; 2019:5245063. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863781
  7. Seftel AD. Re: Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association. The Journal of urology 2019:10109701ju00005547914083509. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888895
  8. LaBoy SM, Pulley MT. Statin Associated Muscle Symptoms: Does the benefit outweigh the risk factor? Muscle Nerve 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30882912
  9. Martin Navarro JA, Gutierrez Sanchez MJ, Petkov Stoyanov V, Jimenez Herrero MC. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30798999
  10. Bouitbir J, Sanvee GM, Panajatovic MV et al. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877064
  11. Fogacci F, Banach M, Mikhailidis DP et al. SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Pharmacol Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30844537
  12. Shrestha A, Mulmi A, Munankarmi R. Statins and Abnormal Liver Enzymes. South Dakota medicine : the journal of the South Dakota State Medical Association 2019; 72:12-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30849222
  13. Watanabe K, Oda S, Matsubara A et al. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. Toxicology letters 2019; 307:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=30853469
  14. Curry L, Almukhtar H, Alahmed J et al. Simvastatin inhibits L-type Ca2+-channel activity through impairment of mitochondrial function. Toxicological sciences : an official journal of the Society of Toxicology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859212
  15. Lundberg E, Hagberg O, Jahnson S, Ljungberg B. Association between occurrence of urinary bladder cancer and treatment with statin medication. Turkish journal of urology 2019; 45:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875287

Stroke and CNS

  1. Godinho R, Bugnon S, Gracin T, Tataw J. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya(R) (EVG/COBI/FTC/TAF) and simvastatin; a case report. BMC Nephrol 2019; 20:69. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808332
  2. Ahmadizar F, OchoaRosales C, Glisic M et al. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30838685
  3. Hosio M, Urpilainen E, Marttila M et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Res Treat 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30895533
  4. Sroda-Pomianek K, Michalak K, Palko-Labuz A et al. The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells. Int J Mol Sci 2019; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30813251
  5. Khan SU, Rahman H, Okunrintemi V et al. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2019; 8:e011581. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898075
  6. Zhu K, Qian L, Lin Y et al. Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. Journal of diabetes research 2019; 2019:5245063. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863781
  7. Seftel AD. Re: Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association. The Journal of urology 2019:10109701ju00005547914083509. http://www.ncbi.nlm.nih.gov/pubmed/?term=30888895
  8. LaBoy SM, Pulley MT. Statin Associated Muscle Symptoms: Does the benefit outweigh the risk factor? Muscle Nerve 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30882912
  9. Martin Navarro JA, Gutierrez Sanchez MJ, Petkov Stoyanov V, Jimenez Herrero MC. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30798999
  10. Bouitbir J, Sanvee GM, Panajatovic MV et al. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30877064
  11. Fogacci F, Banach M, Mikhailidis DP et al. SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Pharmacol Res 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30844537
  12. Shrestha A, Mulmi A, Munankarmi R. Statins and Abnormal Liver Enzymes. South Dakota medicine : the journal of the South Dakota State Medical Association 2019; 72:12-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30849222
  13. Watanabe K, Oda S, Matsubara A et al. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. Toxicology letters 2019; 307:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=30853469
  14. Curry L, Almukhtar H, Alahmed J et al. Simvastatin inhibits L-type Ca2+-channel activity through impairment of mitochondrial function. Toxicological sciences : an official journal of the Society of Toxicology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859212
  15. Lundberg E, Hagberg O, Jahnson S, Ljungberg B. Association between occurrence of urinary bladder cancer and treatment with statin medication. Turkish journal of urology 2019; 45:97-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=30875287

Triglycerides/HDL

  1. Lin A, Nerlekar N, Rajagopalan A et al. Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. Atherosclerosis 2019; 284:24-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870704
  2. Alexopoulos AS, Qamar A, Hutchins K et al. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Current diabetes reports 2019; 19:13. http://www.ncbi.nlm.nih.gov/pubmed/?term=30806837
  3. Femlak M, Gluba-Brzozka A, Franczyk B, Rysz J. Diabetes-induced Alterations in HDL Subfractions Distribution. Current pharmaceutical design 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30827232
  4. Riaz H, Khan SU, Rahman H et al. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol 2018:2047487318816495. http://www.ncbi.nlm.nih.gov/pubmed/?term=30861690
  5. Bhatt DL, Steg PG, Miller M et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898607

Trials

  1. Kurihara O, Thondapu V, Kim HO et al. Comparison of Vascular Response to Statin Therapy in Patients With Versus Without Diabetes Mellitus. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851939
  2. Thondapu V, Kurihara O, Yonetsu T et al. Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization. Am J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851941
  3. Suzuki K, Oikawa T, Nochioka K et al. Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. Arterioscler Thromb Vasc Biol 2019:Atvbaha119312336. http://www.ncbi.nlm.nih.gov/pubmed/?term=30866657
  4. Kim K, Lee CJ, Shim CY et al. Statin and clinical outcomes of primary prevention in individuals aged >75years: The SCOPE-75 study. Atherosclerosis 2019; 284:31-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870705
  5. Csaszar A. The characteristics of two LDL-cholesterol level reduction treatment strategies, "treat-to-target" and "percent reduction": an observational study without intervention. BMC Cardiovasc Disord 2019; 19:57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30857520
  6. Chen Y, Yuan Z, Lu J et al. Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30851062
  7. Lorenzatti AJ, Eliaschewitz FG, Chen Y et al. Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial. Diabetes Obes Metab 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821053
  8. Kawasaki R, Kitano S, Sato Y et al. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetology international 2019; 10:3-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30800559
  9. Ihm SH, Shin J, Park CG, Kim CH. Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito((R))) in Korean adults with hypertension and hypercholesterolemia. Drug design, development and therapy 2019; 13:633-645. http://www.ncbi.nlm.nih.gov/pubmed/?term=30858694
  10. Kwak A, Kim JH, Choi CU et al. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over. Int J Clin Pharm 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30864086
  11. Bhatt DL, Steg PG, Miller M et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898607
  12. Jukema JW, Szarek M, Zijlstra LE et al. Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898609
  13. Chan DC, Watts GF, Coll B et al. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. J Am Heart Assoc 2019; 8:e011781. http://www.ncbi.nlm.nih.gov/pubmed/?term=30897995
  14. Lo-Kioeng-Shioe MS, Vavere AL, Arbab-Zadeh A et al. Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE 320 Multinational Study. J Am Heart Assoc 2019; 8:e007201. http://www.ncbi.nlm.nih.gov/pubmed/?term=30879377
  15. Yamamoto H, Kawamura M, Kochi I et al. Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment. J Atheroscler Thromb 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30867375
  16. Amioka N, Miyoshi T, Otsuka H et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Cardiol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30898480
  17. Zhu K, Qian L, Lin Y et al. Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. Journal of diabetes research 2019; 2019:5245063. http://www.ncbi.nlm.nih.gov/pubmed/?term=30863781
  18. Tomoi Y, Yamaji K, Soga Y et al. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 2019:1526602819836382. http://www.ncbi.nlm.nih.gov/pubmed/?term=30873910
  19. Mani P, Puri R, Schwartz GG et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA cardiology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30840024
  20. Kim MC, Ahn Y, Cho JY et al. Benefit of Early Statin Initiation within 48 Hours after Admission in Statin-Naive Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Korean Circ J 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808084
  21. Hopkin G, Au A, Collier VJ et al. Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. Med Decis Making 2019:272989x19835239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30873906
  22. Ray KK, Bays HE, Catapano AL et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380:1022-1032. http://www.ncbi.nlm.nih.gov/pubmed/?term=30865796
  23. Bosch J, O'Donnell M, Swaminathan B et al. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30814321

Women and elderly

  1. Kim K, Lee CJ, Shim CY et al. Statin and clinical outcomes of primary prevention in individuals aged >75years: The SCOPE-75 study. Atherosclerosis 2019; 284:31-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=30870705
  2. Tian J, Wang X, Tian J, Yu B. Gender differences in plaque characteristics of nonculprit lesions in patients with coronary artery disease. BMC Cardiovasc Disord 2019; 19:45. http://www.ncbi.nlm.nih.gov/pubmed/?term=30808307
  3. Hosio M, Urpilainen E, Marttila M et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Res Treat 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30895533
  4. Sundvall H, Fastbom J, Wallerstedt SM, Vitols S. Use of statins in the elderly according to age and indication-a cross-sectional population-based register study. Eur J Clin Pharmacol 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30826850
  5. Khan NNS, Kelly-Blake K, Luo Z, Olomu A. Sex Differences in Statin Prescribing in Diabetic and Heart Disease Patients in FQHCs: A Comparison of the ATPIII and 2013 ACC/AHA Cholesterol Guidelines. Health services research and managerial epidemiology 2019; 6:2333392818825414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30859113
  6. Kwak A, Kim JH, Choi CU et al. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over. Int J Clin Pharm 2019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30864086
  7. Offer A, Arnold M, Clarke R et al. Assessement of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA network open 2019; 2:e190223. http://www.ncbi.nlm.nih.gov/pubmed/?term=30821829

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.